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Abstract
Allogeneic stem cell transplantation has a well-defined
indication in the treatment of hematological malignan-
cies. The beneficial immune effect of allogeneic marrow
transplantation has long been known, but only recently
have methods been developed to separate the graft-ver-
sus-leukemia (GVL) effect from graft-versus-host disease
(GVHD). Animal experiments have shown that lympho-
cytes from the marrow donor can be transfused without
causing severe GVHD if stable chimerism and tolerance
is established. First clinical studies have been preformed
in patients with recurrent chronic myelogenous leuke-
mia. In these patients complete molecular remissions
were induced that persist without further maintenance
treatment. These results have been confirmed in larger
multicenter studies in Europe and the USA. The best
results were obtained in chronic myelogenous leukemia
(CML); repeated successes have been reported in relaps-
ing acute myeloid leukemia (AML), myelodysplastic syn-
dromes and multiple myeloma (MMY), and rare re-
sponses were reported for acute lymphoid leukemia.
Contrary to animal experiments GVHD has been ob-
served in human patients although to a lesser extent
than expected in transplants not given immunosuppres-
sion. Secondly myelosuppression has been observed in
patients treated with relapsing CML. In CML the inci-
dence of GVHD could be reduced by depleting CD8+ T
cells from the donor lymphocyte concentrate. Alterna-
tively only small numbers of T lymphocytes can be trans-
fused and in the case of failing responses, the numbers
of donor lymphocytes may be increased. Results in
recurrent AML have been improved by the use of low-
dose cytosine arabinoside, granulocyte-macrophage
colony-stimulating factor and granulocyte colony-stimu-
lating factor mobilized blood cells as compared to lym-
phocytes only. In MMY the response rate is higher than
in AML, but the remissions are of limited duration in
most patients. Several protocols have been designed to
include preemptive donor lymphocyte transfusion in pa-
tients with a high relapse risk after transplantation. Prob-
lems remain to avoid chronic GVHD and to circumvent
the immune escape mechanisms of leukemia.
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The success of donor lymphocytes in the treatment of
recurrent leukemia has changed the perspectives of hema-
topoietic stem cell transplantation [1]. The antileukemic
effects of myeloablative conditioning have been substi-
tuted by adoptive immunotherapy using cells of the mar-
row donor (fig. 1). Formerly the treatment of leukemia
and other neoplastic diseases of the hematopoietic system
focused on the maximal tolerated dose of radiation and
chemotherapy to destroy the leukemia as much as possi-
ble and to rescue the patient from hematopoietic failure
by transplanting bone marrow. Today the limitations and
risks of high-dose chemotherapy and radiotherapy are
well known and the conditioning treatment is designed to
allow the establishment of chimerism and the develop-
ment of transplantation tolerance as a platform for immu-
notherapy. The conditioning does not need to be myelo-
ablative. There is a therapeutic dilemma in bone marrow
transplantation for malignant diseases. Acute graft-ver-
sus-host disease (GVHD) and its sequelae are the major
complications of allogeneic stem cell transplantation. The
most effective method to prevent GVHD is the depletion
of T lymphocytes from the transplant [2, 3]. However, the
depletion of T cells from the graft ablated most of the anti-
leukemic effect of allogeneic transplantation [4]. Adding
back small amounts of T cells to the depleted graft was not
successful in reducing the risk of relapse without inducing
GVHD. However, transfusion of donor lymphocytes into
stable canine chimeras did not produce GVHD [5].
Therefore in the 1980s we studied donor lymphocyte
transfusions (DLTs) in canine chimeras with the aim of
influencing chimerism and transfer immunity from the
donor to the host [6].
The animal experiments encouraged us to use donor
lymphocytes for the treatment of relapse of chronic my-
elogenous leukemia (CML) in 3 patients [7]. The results
were confirmed by several single centers [8–14], and the
spectrum of graft-versus-leukemia (GVL) activity was
assessed in multicenter analyses [15, 16]. Native donor
lymphocytes and sensitized T cells, T-cell lines and clones
were successful in the treatment of viral infections [17–
19]. Similar strategies have been explored using minor
histocompatibility antigens with restricted tissue expres-
sion in the treatment of leukemia [20–22]. Here we review
the current status of adoptive immunotherapy with donor
cells and we try to give a perspective to the future of
immunotherapy.
Fig. 1. Strategy of adoptive immunotherapy
in chimeras. Adoptive immunotherapy with
T cells with or without dendritic cells allows
non-myeloablative conditioning. As soon as
chimerism is stable and immunosuppression
can be discontinued, a state of immunologi-
cal tolerance is established. At this time do-
nor cells can be transfused without severe
GVHD.
Non-myeloablative conditioning
stem cell transplantation
S
Chimerism & Tolerance
S
Adoptive immunotherapy with
specific T-cells B dendritic cells
Principles Derived from Animal Studies
There have been many studies on murine leukemia
which differs in several aspects from human leukemia.
Bacteria-free mice with spontaneous AKR leukemia have
been treated with some success using marrow and low-
dose lymphocytes from major histocompatibility complex
(MHC) mismatched donors [23].
The concept that leukemia expresses minor histocom-
patibility antigens on the hematopoietic cells of the host
was the starting point for the production of mixed DLA-
identical chimeras in dogs. Conversion of mixed chimer-
ism into complete chimerism served as a model for a GVL
reaction. Mixed chimeras were produced by transplanta-
tion of low numbers of marrow cells depleted of T cells by
the treatment with absorbed antithymocyte globulin
(ATG) to prevent GVHD. These animals were stable
mixed chimeras. Transfusion of donor lymphocytes on
days 1 and 2, or days 21 and 22 after marrow transplanta-
tion induced fatal GVHD. However, transfusion on days
61 and 62 did not produce GVHD and the animals sur-
vived. These animals were mixed lymphoid and myeloid
chimeras prior to transfusion and they became complete
chimeras thereafter [6]. The donors were immunized
against tetanus toxoid and the recipients developed anti-
body titers after DLT that persisted for more than 3 years
after booster injections. Transfused and nontransfused
animals were immunized against diphtheria toxoid as a
new antigen. Transfused dogs developed significantly
higher antibody titers than nontransfused dogs.
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Fig. 2. The course of a 39-year-old patient
suffering from myelosuppression following
DLT. After DLT WBC increased and the
patient developed fever until the blood
counts dropped and the patient became se-
verely pancytopenic. Transfusion of marrow
from his donor without further conditioning
resulted in complete restoration of hemato-
poiesis and complete chimerism. A molecu-
lar remission was found after marrow trans-
fusion that persists until presence.
In mice a delay of 3 weeks for the transfusion of donor
lymphocytes was enough to prevent GVHD [24].
The importance of the delay of DLT is obvious, but the
cause of GVHD is not clear. One possibility is the ‘cyto-
kine storm’ set free by the conditioning treatment with
radiation and chemotherapy [25] that may have settled
after 3 weeks and 2 months, respectively. Another possi-
bility is the establishment of peripheral tolerance main-
tained by donor T cells in collaboration with host dendrit-
ic cells. The latter mechanism is supported by the finding
that depletion of donor lymphocytes in the chimera prior
to DLT predisposes the recipient to vigorous GVHD
(Menzel H, 1996, unpublished) [26]. In man the necessary
delay is not known. It may vary with age and previous
chemo- and radiotherapy.
Results of DLTs in CML
Three patients with recurrent CML after allogeneic
marrow transplantation were treated with DLT in 1988
and 1989 [27], they are still in hematologic and molecular
remission of CML. Acute GVHD developed in 2 patients
requiring immunosuppressive treatment, and chronic
GVHD in 1. Immunosuppressive treatment could be dis-
continued in both. Severe myelosuppression was ob-
served in a 4th patient treated 1991. Pancytopenia oc-
curred 2 months after DLT and it did not respond to
treatment with granulocyte colony-stimulating factor, but
to the transfusion of donor marrow (fig. 2).
The analysis of the results of centers of the European
Cooperative Group of Blood and Marrow Transplanta-
tion (EBMT) showed best results in cytogenetic and
hematologic relapses of CML, intermediate results in
transformed phase CML, acute myeloid leukemia (AML)
and myelodysplastic syndromes (MDS), and poor results
in acute lymphoblastic leukemia (ALL) [15]. Single pa-
tients with chronic myeloproliferative diseases as polycy-
themia vera and myeloid fibrosis [28] also responded to
DLT. Both the absence of chimerism [29] and the pres-
ence of GVHD at the time of DLT were adverse factors
for a response. In CML the GVL effect correlated with the
severity of GVHD, but responses were also seen in
patients without GVHD. However GVL was limited to
patients with an allogeneic donor, it failed in patients with
a monozygotic twin donor. The time until molecular
remission was between 4 and 6 months after a single
transfusion in most patients; in some patients molecular
remissions were reached after more than a year (fig. 3).
Antigen presentation could be improved by treatment
with cytokines. In particular the combination of interfer-
on-· (IFN-·) and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) improved the expression of class-I
and II human lymphocyte antigens (HLAs), CD40 and
CD80 [30]. Preliminary results confirm the beneficial
effect of GM-CSF and IFN-· in patients with recurrent
CML refractory to donor lymphocytes.
Complications of the treatment were GVHD and
myelosuppression. Myelosuppression was more frequent
in hematological relapse than in cytogenetic relapse. The
Adoptive Immunotherapy in Chimeras with
Donor Lymphocytes
Acta Haematol 2003;110:110–120 113
use of mobilized blood cells containing stem cells instead
of lymphocytes did not prevent myelosuppression [31].
Prevention of GVHD could be achieved by two methods
without ablating the GVL effect: depletion of CD8+ T
cells from the transfusion [32, 33], and using escalating
doses of DLT [34] starting at 2 ! 106 lymphocytes/kg.
The escalating dose schedule has significantly lowered the
risk of GVHD [35]. Patients should be surveyed by regu-
lar quantitative reverse transcriptase polymerase chain
reaction for bcr/abl, and in case of persisting or recurrent
positivity the proposed schedule is started at a dose of 2 !
106 lymphocytes/kg from unrelated donors and 1 ! 107
lymphocytes/kg from an HLA-identical sibling donor.
Doses are escalated if there is no GVHD within 30 days or
no response within 60 days.
Results of DLTs in AML and MDS
The EBMT results indicated inferior responses in pa-
tients with recurrent AML after DLT. In patients without
chemotherapy-induced remission the response rate was
25% with very few patients surviving more than 4 years.
In a second analysis of 120 patients with AML and MDS
reported to the EBMT, complete remissions could be
induced in 45 (41.6%) of 108 evaluable patients including
patients treated with chemotherapy and DLT [36]. The
median duration of remission was 304 days, in 18 pa-
tients remissions lasted more than a year, and in single
patients more than 5 years. Overall survival was greater in
responding patients. Three risk factors could be identified
as being associated with a poor response to DLT: a short
remission after allogeneic transplantation of less than the
median of 194 days (p = 0.02); withholding chemotherapy
prior to DLT (p = 0.001), and the absence of acute GVHD
of grade II or higher after DLT (p ! 0.0001). Of patients
without GVHD only 18% responded as compared to 66%
of patients with GVHD 1 grade I. Patients with late
relapse after transplantation responded more frequently
(48%) than those with early relapse (28%). After DLT the
complete remission rate was independent of gender and
age of the patient and donor, their relationship, the num-
ber of cells transfused and whether or not T-cell depletion
was used for prophylaxis of GVHD after transplantation.
Survival of patients without complete remission was
poor, but once a complete remission was achieved surviv-
al was not different whether or not the remission was
induced by chemotherapy. This finding supports the hy-
pothesis that DLT maintains the remission and favors the
use of chemotherapy for remission induction.
Fig. 3. Time to molecular remission after DLT. Molecular remis-
sions were achieved after 4 months, the median time was 6 months
and late remissions occurred after more than 1 year. Data are from
the Transplant Center Munich Grosshadern, evaluated in March
2001.
Only limited data were available on the FAB subtype
and cytogenetic analyses in these patients. With these lim-
itations neither the FAB subtype nor the karyotype in-
fluenced the response.
Poor antigen presentation and the rapid progression of
the disease were considered as the major obstacles for
adoptive immunotherapy in recurrent AML. Improve-
ment of antigen presentation and production of cytotoxic
T cells against autologous blasts was studied in vitro
(fig. 4). The combination of GM-CSF, IL-4, TNF-· and
FLT3-L was particularly effective in inducing dendritic
cells from AML blasts [37]. The culture was effective in
77% of patients and included patients with unfavorable
karyotypes. Specific cytotoxic T cells against autologous
blasts could be produced in more than 60% of these
patients.
In a recent study we have used low-dose cytosine arabi-
noside as mild chemotherapy for halting progression of
the disease and GM-CSF for improving antigen presenta-
tion. Mobilized blood (MDBC) was transfused as a prepa-
ration of stem cell-enriched donor lymphocytes and GM-
CSF was applied for 14–28 days after transfusion. This
way antigen presentation was optimized by induction of
dendritic cells from AML blasts and substitution of den-
dritic cells derived from CD34+ cells of the graft. The
response rate was improved from 25 to 67% and the
actuarial probability of survival is 25% at 4 years [38]. In
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Fig. 4. Pathophysiology of GVHD. There is mutual activation of
donor CD4+ T cells and host dendritic cells which may be acceler-
ated by pre-activation of dendritic cells by radiation, chemotherapy,
endotoxin from intestinal flora, viral infections and by pre-immuni-
zation on the side of the T cells against minor histocompatibility anti-
gens, viral antigens and others. Activated dendritic cells activate
CD8+ T cells and present HLA class-I-restricted peptides to CD8 T
cells which become activated and react against normal cells of the
host.
some responding patients the treatment was repeated
after 4–6 months, and the patients have remained in
remission.
In patients with progressive disease after MDBC, low-
dose cytosine arabinoside and the transfusion of donor T
cells has been used with success, but GVHD was mostly
severe.
GVHD and extramedullary relapses remain therapeut-
ic problems. In most patients with extramedullary relapse
and some patients with systemic relapse, low-dose cyto-
sine arabinoside is not effective in halting disease progres-
sion. In these more intensive chemotherapy including
anthracyclins is necessary; solitary infiltrates may be
radiated prior to transfusion of donor cells [39]. Following
more intensive chemotherapy severe GVHD may devel-
op after transfusion of mobilized blood cells and treat-
ment with GM-CSF. In these cases GM-CSF has to be
stopped and immunosuppressive treatment with steroids,
cyclosporin A and azathioprine or others has to be started.
GM-CSF should also be discontinued if blasts are mobil-
ized from the marrow into the blood. Unfortunately leu-
kemia may recur during immunosuppressive treatment
and few therapeutic options remain.
Results of DLTs in Myeloma
The best responses next to CML were seen in recurrent
multiple myeloma [40–42]. The most sensitive marker for
response is the monoclonal paraprotein, next are infil-
trates of plasma cells in the marrow and the disappear-
ance of lumps, and the least sensitive are osteolytic
lesions. The time to response may be 4–6 months or lon-
ger, and unlike in CML hematological remissions are less
likely to be complete [43]. In most instances remissions
are not as durable as in CML, but durable partial remis-
sions have been observed in single patients (Kolb, unpub-
lished). GVHD is observed in most responding patients, it
may even recur after chemotherapy for myeloma [44].
Prevention of GVHD by depletion of CD8+ T cells from
DLT was used with some success [33], repeated low doses
of unseparated DLT were also effective [45].
Preemptive treatment with DLT may improve the out-
come in combination with T-cell depletion, but the opti-
mal strategy has not been found [46]. Immunization of a
donor against the idiotype of the myeloma and the trans-
fer of a cellular proliferative response has been reported
[47], but the reactive donor T cells were found in the
patient with persisting paraprotein.
Results of DLTs in Other Diseases
The response of recurrent ALL to DLT was poor in
most cases [5, 48], but there are exceptions with long-last-
ing remissions [49, 50]. The first case of Slavin et al. [13]
was a child with ALL who received donor cells 4 weeks
after transplantation for residual leukemia. Remissions
have been described in patients with Hodgkin’s disease,
non-Hodgkin’s lymphoma [51] and chronic lymphocytic
leukemia, but the overall response is controversial.
Neoplastic diseases other than hematological have
been treated with allogeneic transplantation and DLT
with some success. Metastatic renal cell cancer has shown
sustained responses [52], some response was also ob-
served in breast [53] and ovarian cancer (Kolb unpub-
lished).
Non-malignant diseases have benefited from DLT in
cases of poor graft function after non-myeloablative con-
ditioning [54]. Allogeneic transplantation and DLT have
been advocated for the treatment of autoimmune diseases
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[55], since patients with autoimmune disease who had
been transplanted for leukemia were cured of the autoim-
mune disease in most instances. However, chronic
GVHD may complicate allogeneic stem cell transplanta-
tion after non-myeloablative conditioning with symptoms
similar to those of autoimmune diseases.
DLTs have been used for the treatment of viral infec-
tions after transplantation, in particular Epstein-Barr vi-
rus-induced lymphoproliferative disease [18]. In these
cases minute numbers of T cells were sufficient and the
reactions were associated with an acute inflammatory
response. Pre-immunized T-cell lines were better tolerat-
ed and effective [19]. Adoptive immunotherapy of viral
infections has shown promising results which may lead to
better understanding of the GVL response.
Mechanism of the GVL (Tumor) Effect
The absence of a measurable GVL effect in patients
with syngeneic twin donors indicates the importance of an
alloimmune response [15]. Minor histocompatibility anti-
gens are expressed on leukemia cells and can serve as tar-
gets for a GVL effect without GVHD, if their expression
is restricted to hematopoietic tissue [22, 56]. HA-1 and
HA-2 are such peptides with restricted expression to the
hematopoietic system, but Y-associated minor histocom-
patibility antigens are also candidates [57, 58]. Tissue-
restricted expression of minor histocompatibility antigens
may be operationally limited to the hematopoietic system
by presentation of class-II HLAs [59].
The effector cells of the GVL reaction are not well
defined. CD4+ T cells might be candidates, since CD8+ T
cells could be depleted without losing the GVL effect [32].
However CD4+ T cells can recruit CD8+ T cells and other
cells in vivo [60].
There is good evidence that ex vivo T cells immunized
against minor histocompatibility antigens effectively lyse
leukemia cells in vitro [21, 61] and in immunodeficient
mice in vivo [62]. However, ex vivo immunized T cells
have not yet been used widely in human patients. The
most convincing example of leukemia treatment with
immunized cells is the trial of Falkenburg et al. [63] who
selected cytotoxic T cells on the basis of their reactivity to
CML cells and infused them repeatedly into a patient
with accelerated phase CML. Slavin et al. [64] immunized
donor cells with cell lysates of the parents and found a
complete response in a patient with accelerated phase
CML who had not responded to DLT.
Antigens other than minor histocompatibility antigens
that may be candidates for a GVL effect comprise fusion
peptides, peptides from proteins encoded by mutated
genes and proteins of overexpressed genes. Products of
disease-specific rearranged genes as BCR/ABL in CML,
PML/RAR· in AML FAB M3 and AML1/ETO and oth-
ers contain highly specific fusion peptides. Proteins of
genes with point mutations as in RAS genes and peptides
of overexpressed normal genes such as p53 and proteinase
3 [65] have been studied. The antibody idiotype of a lym-
phoma and myeloma could also be seen as an overex-
pressed normal protein that marks the tumor. T-cell reac-
tivity has been described for all of these, but only BCR/
ABL-specific T cells recognize malignant cells in patients,
and T cells with that specificity are occasionally found in
patients [66]. To date none of these antigens has been
used successfully for adoptive immunotherapy in chimer-
ic patients [67].
Our hypothesis that because myeloid leukemia pro-
duces dendritic cells of leukemia origin it responds better
to DLT than lymphoid leukemia has been supported by
the finding that dendritic cells in CML carry the bcr/abl
translocation [30, 68, 69], and AML cells differentiated
the karyotypic marker to dendritic cells [37, 70] in fluores-
cent in situ hybridization (FISH).
The production of dendritic cells from leukemia pre-
cursors has been studied in vitro because most cases of
AML, as lymphomas and lymphoblastic leukemia, do not
express co-stimulatory molecules such as CD80 and
CD86. Untreated CML is poorly stimulatory in mixed
lymphocyte reactions and fails to induce cytotoxic T cells
in many instances [71]. Culture of AML blasts in the pres-
ence of GM-CSF, IL-4 with or without TNF-· and FLT3-
L induces the expression of co-stimulatory molecules [37]
(fig. 5). Similarly culture of CML cells in the presence of
IFN-· and GM-CSF stimulates expression of co-stimula-
tory molecules and the generation of cytotoxic T lympho-
cytes [72]. The combination of GM-CSF and IFN-· has
already been used successfully in patients with relapse of
CML not responding to DLT alone and DLT plus IFN-·
(unpublished). Other cytokines such as IL-2 have been
introduced on the basis of animal experiments [73]. IL-2
may support the T-cell reactivity after immunization. In
myeloma and lymphoid neoplasms stimulation of donor
T cells is poor and new ways to improve specific T-cell
stimulation are being explored. One possibility is the
transfer of genes coding for immunostimulatory mole-
cules and proinflammatory cytokines [74]. Other ways are
the transfusion of dendritic cells with the DLT or the use
of MDBC together with the treatment with GM-CSF.
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Fig. 5. AML cells may develop to antigen-presenting cells. AML
blasts are deficient of co-stimulatory molecules and are thus ineffi-
cient in the presentation of antigen to donor T cells. Treatment with
GM-CSF drives blasts to express the stimulatory molecules necessary
for efficient antigen presentation. These T cells then react against
residual blasts.
Fig. 6. Mechanism of the graft-versus-leuke-
mia reaction. After establishment of chimer-
ism dendritic cells of the host are replaced by
dendritic cells of the donor. Leukemic blasts
are potentially the remaining hematopoietic
cells of the host which may become stimula-
tory and a target for donor T cells, if they are
driven towards dendritic cells. The reaction
is specific because minor histocompatibility
antigens with restricted expression are in-
volved and donor dendritic cells maintain
tolerance in other organs.
Table 1. Possible mechanisms of immune escape
Mechanisms on antigen presentation
Low expression of co-stimulatory molecules: B7.1, B7.2, CD40,
ICAM
Downregulation of HLA class I, class II antigens or relevant alleles
Inefficient peptide production by proteasome/TAP mechanism
Secretion of inhibitory cytokines as IL-10, TGF-ß
Low secretion of proinflammatory cytokines TNF-· and IFN-Á
Expression of FAS-L on tumor/leukemia cells inducing apoptosis of
T cells
Expression of nonfunctional FAS on leukemia blasts
Mechanisms on T cells
Downregulation of @-chain (lymphoma and CML) and Â-chain
(CML) of the T cell receptor
Downregulation of CD28 in AML
Others
Immune reconstitution after DLT has been studied
with typing for T-cell receptor V-ß families [75] and T-cell
receptor excision circles [76]. DLT enhanced immune
recovery and converted to full donor chimerism. In single
patients with GVL reactions clonal T-cell restitution has
been observed [75]. T cells of the donor produced similar
clones when exposed to the leukemia in vivo as in vitro,
but genetic analysis showed that they were different [77].
Intercurrent infections with viruses or other intracellu-
lar microorganisms may jeopardize the result of DLT.
Most patients experiencing viral infections in the first
weeks after DLT develop GVHD. A similar observation
has been reported in patients given T-cell-depleted trans-
plants and DLT. CMV seropositivity of the patient was
the most significant risk factor for survival [78]. It is being
discussed whether anti-infectious prophylaxes should be
given to patients after DLT.
There are numerous mechanisms how neoplasms and
leukemia may escape an immune reaction against them-
selves (table 1) [79]. Most importantly the expression of
antigens on the cell surface may change. Even the loss of
the Philadelphia chromosome has been reported [80]. In
this context the use of minor histocompatibility antigens
is most promising, because in the chimera most hemato-
poietic cells are substituted by the donor and only leuke-
mia cells are still of host type (fig. 6).
The role of natural killer (NK) cells has always been
debated in allogeneic stem cell transplantation. During
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post-transplant recovery NK cells are early and trials of
substitution early after transplantation have not been suc-
cessful. In murine models allogeneic NK cells were effec-
tive [81], but depletion of CD3+ T cells abrogated the
effect [82]. In HLA-mismatched transplantation complete
T-cell chimerism is not required for GVL to occur, mixed
chimeras can be cured of lymphoma [83]. In mixed chi-
meras DLT exert a strong effect against lymphoma with-
out causing GVHD [84]. The role of NK cells has recently
been investigated in HLA-mismatched transplantation
and excellent results were reported in AML, if donor and
patient differed in the killer inhibitor receptors [85]. NK
cells are inhibited from killing if the target cells share cer-
tain HLA antigens. In HLA-mismatched transplantation
NK cells of the donor can kill leukemia cells and at the
same time suppress rejection of the transplant. In the case
of the donor and patient belonging to a different alloreac-
tive group, relapses of AML did not occur.
Outlook for Adoptive Immunotherapy
Hematopoietic cell transplantation has come a long
way from bone marrow transplantation to adoptive im-
munotherapy in chimeras. However, the mechanisms of
adoptive immunotherapy in chimeras are still far from
being understood. The immunobiology of leukemia, other
neoplasia and viral infections has to be studied further in
human patients. The mechanism of immune tolerance,
immune reactivity against normal cells, and transfer of
immunity can be studied in animal experiments.
Immunization of donor T cells against minor histo-
compatibility antigens of the recipient is currently studied
in the dog. Sensitized cells convert mixed to complete chi-
merism much faster than naive T cells. Tests have been
developed to demonstrate cellular immunity to hemato-
poietic progenitor cells in vitro allowing the definition of
minor antigens in the dog [86]. The incidence of severe
GVHD after transfusion of sensitized donor lymphocytes
into stable chimeras may be 30–50% [5]. The percentage
is expected to be higher in humans since patients and their
donors are exposed to a multiplicity of histocompatibility
and viral antigens during their life. Preventive measures
against severe GVHD are necessary. Modification of do-
nor lymphocytes with a suicide gene is the most promising
way of prevention. T cells of the donor are infected with a
replication-deficient retrovirus carrying the herpes sim-
plex thymidine kinase gene (HSV-Tk) which can phos-
phorylate ganciclovir and the resulting nucleotide leads to
the stop of DNA polymerization during cell division [87].
Current problems of the method are altered immune reac-
tivity of transduced T cells, immune reaction against the
viral protein and rejection of the transduced cells and
altered sensitivity of transduced cells to ganciclovir due to
splice variants of the gene. Recently the development of
leukemia has been reported in a mouse treated with cells
carrying the marker gene (a truncated nerve growth factor
receptor) without the suicide gene. We have studied the
method in the dog and found a good immune reactivity of
transduced canine T cells in vitro. Transfusion of trans-
duced T cells into a canine chimera resulted in a complete
chimerism and transfer of immunity to tetanus toxoid
[88].
Adoptive immunotherapy in chimeras is a promising
way to treat leukemia and possibly solid neoplasia. In par-
ticular the immune reactivity against leukemias and neo-
plasia otherwise refractory to chemotherapy gives new
perspectives in hematology and oncology. Several leuke-
mia study groups have included preemptive DLT as pro-
phylaxis in high-risk leukemia according to the schema
shown in figure 1. The results are pending.
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